好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Wearable-based Monitoring of Physical Activity and Upper Limb Function in Inclusion Body Myositis
Neuromuscular and Clinical Neurophysiology (EMG)
S7 - Updates on Muscle Disorders (4:18 PM-4:30 PM)
005

To validate at-home digital biomarkers for monitoring changes in upper and lower limb function in Inclusion Body Myositis (IBM).

IBM results in physical disability due to progressive muscle weakness. Assessment of function is quantified in clinical care and research settings using a combination of clinician-assessed scales for muscle strength and function, as well as the IBM Functional Rating Scale (IBMFRS).

This is a 24-month prospective study in 20 IBM patients undergoing assessments at baseline, 6, 12, 18, and 24 months. IBMFRS is assessed during each visit along with strength measures and patient-related outcomes. Participants are given a PAMSysTM pendant and 2 PAMSys ULMTM wrist sensors for at-home monitoring of physical activity, posture and upper limb function for 7 consecutive days after each visit.

Twenty participants have been enrolled in the study. An interim analysis of the first 19 individuals diagnosed with IBM (mean age 71.0±7.3 years, 11 female) with IBMFRS ranging 14 to 35 show that sensor-derived measures of physical activity collected after the baseline visit have significant correlation with the lower extremity subdomain score of the IBMFRS (items 7–10) with correlations ranging from r =-0.559 to 0.674. Similarly, sensor-derived measures of hand function demonstrated moderate to strong correlations with the upper extremity subdomain score of the IBMFRS (items 2–6), with correlations r = 0.509 to 0.615.

While this study is ongoing, interim analysis of the baseline data indicate that at home wearable-based monitoring has the potential to track physical dysfunction in IBM effectively. Wearable sensors provide objective data, increased convenience, and offer scalability and cost-effectiveness, thereby advancing clinical care and potentially improving future clinical trials in IBM. We plan to present data on all 20 participants at the meeting.

Authors/Disclosures
Mazen M. Dimachkie, MD, FAAN (University of Kansas Medical Center)
PRESENTER
Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Octapharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Takeda. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medlink. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Astellas. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dianthus. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for TACT / Treat NMD. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Neurological Society of America, Inc . Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Ig Society, Inc. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abcuro. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/Immunovant. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for 好色先生 (AAN). Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon Biosciences. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Candid Therapeutics. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Creyon Bio, Inc.. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig Therapeutics. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB Biopharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceuticals. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fortrea. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kriya Therapeutics. The institution of Dr. Dimachkie has received research support from NIH. The institution of Dr. Dimachkie has received research support from The Myositis Association. The institution of Dr. Dimachkie has received research support from Biosensics. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care.
Tejas Pawar, Researcher Mr. Pawar has nothing to disclose.
Ram Kinker Mishra, PhD (Biosensics) Dr. Mishra has received personal compensation for serving as an employee of BioSensics LLC.
Samantha Colgan, MAS, CCRP Miss Colgan has nothing to disclose.
Claire Hennum Ms. Hennum has nothing to disclose.
Andrew Heim Andrew Heim has nothing to disclose.
ILKAY YILDIZ POTTER, PhD Dr. YILDIZ POTTER has received personal compensation for serving as an employee of BIOSENSICS LLC.
Hanna Thesken Miss Thesken has received personal compensation for serving as an employee of BioSensics.
Matthew Varon, MD (University of Kansas Medical Center) Dr. Varon has nothing to disclose.
Ashkan Vaziri, PhD (Biosensics LLC) Dr. Vaziri has received personal compensation for serving as an employee of Biosensics.